Wnt5a inhibits hypoxia-induced pulmonary arterial smooth muscle cell proliferation by downregulation of β-catenin

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 304, Issue 2, 2013, Pages

  Yu, Xiao Min ^a,b   Wang, Lei ^a,b   Li, Ji Feng ^a,b   Liu, Jie ^b   Li, Jing ^b   Wang, Wang ^b   Wang, Jun ^a,b   Wang, Chen ^a,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Antiproliferative effect; Chronic hypoxia; Pulmonary arterial hypertension

Indexed keywords

BETA CATENIN; CYCLIN D1; WNT5A PROTEIN;

ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HYPOXIA; LUNG ARTERY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION;

EID: 84872370596     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00070.2012     Document Type: Article

References (43)

1. Cheng CW, Yeh JC, Fan TP, Smith SK, Charnock-Jones DS. Wnt5amediated non-canonical Wnt signalling regulates human endothelial cell proliferation and migration. Biochem Biophys Res Commun 365: 285-290, 2008.
2. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 162: 1495-1502, 2003.
3. Cohen ED, Ihida-Stansbury K, Lu MM, Panettieri RA, Jones PL, Morrisey EE. Wnt signaling regulates smooth muscle precursor development in the mouse lung via a tenascin C/PDGFR pathway. J Clin Invest 119: 2538-2549, 2009.
4. Cui XP, Xing Y, Chen JM, Dong SW, Ying DJ, Yew DT. Wnt/betacatenin is involved in the proliferation of hippocampal neural stem cells induced by hypoxia. Ir J Med Sci 180: 387-393, 2011.
5. de Jesus Perez VA, Alastalo TP, Wu JC, Axelrod JD, Cooke JP, Amieva M, Rabinovitch M. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-β-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol 184: 83-99, 2009.
6. Deguchi JO, Yamazaki H, Aikawa E, Aikawa M. Chronic hypoxia activates the Akt and β-catenin pathways in human macrophages. Arterioscler Thromb Vasc Biol 29: 1664-1670, 2009.
7. Dejana E. The role of wnt signaling in physiological and pathological angiogenesis. Circ Res 107: 943-952, 2010.
8. Du R, Huang C, Bi Q, Zhai Y, Xia L, Liu J, Sun S, Fan D. URG11 mediates hypoxia-induced epithelial-to-mesenchymal transition by modulation of E-cadherin and beta-catenin. Biochem Biophys Res Commun 391: 135-141, 2010.
9. He B, Jablons DM. Wnt signaling in stem cells and lung cancer. Ernst Schering Found Symp Proc: 27-58, 2006.
10. Huelsken J, Birchmeier W. New aspects of Wnt signaling pathways in higher vertebrates. Curr Opin Genet Dev 11: 547-553, 2001.
11. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S, 2004.
12. 2+ pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol 23: 131-139, 2003.
13. Kohn AD, Moon RT. Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium 38: 439-446, 2005.
14. Konigshoff M, Eickelberg O. Wnt signaling in lung disease: a failure or a regeneration signal? Am J Respir Cell Mol Biol 42: 21-31, 2010.
15. Kremenevskaja N, von Wasielewski R, Rao AS, Schöfl C, Andersson T, Brabant G. Wnt5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24: 2144-2154, 2005.
16. Laumanns IP, Fink L, Wilhelm J, Wolff JC, Mitnacht-Kraus R, Graef-Hoechst S, Stein MM, Bohle RM, Klepetko W, Hoda MA, Schermuly RT, Grimminger F, Seeger W, Voswinckel R. The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. Am J Respir Cell Mol Biol 40: 683-691, 2009.
17. Leris AC, Roberts TR, Jiang WG, Newbold RF, Mokbel K. Wnt5a expression in human breast cancer. Anticancer Res 25: 731-734, 2005.
18. Li L, Hutchins BI, Kalil K. Wnt5a induces simultaneous cortical axon outgrowth and repulsive axon guidance through distinct signaling mechanisms. J Neurosci 29: 5873-5883, 2009.
19. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A, Gerstein R, Jurecic R, Jones SN. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4: 349-360, 2003.
20. 2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. Circ Res 95: 496-505, 2004.
21. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810, 2004.
22. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26, 2009.
23. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits β-catenin-TCF signaling depending on receptor context. PLoS Biol 4: e115, 2006.
24. Morin PJ. Beta-catenin signaling and cancer. Bioessays 21: 1021-1030, 1999.
25. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/β-catenin/Tcf signaling axis: Wnt you like to know?. Endocr Rev 26: 898-915, 2005.
26. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30: 2493-2537, 2009.
27. Novak A, Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 56: 523-537, 1999.
28. 2+ channel. Nature 466: 874-878, 2010.
29. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 30: 104-109, 2007.
30. Peng S, Zhang J, Chen J, Wang H. Effects of Wnt5a protein on proliferation and apoptosis in JAR choriocarcinoma cells. Mol Med Report 4: 99-104, 2011.
31. Pukrop T, Klemm F, Hagemann T, Gradl D, Schulz M, Siemes S, Trumper L, Binder C. Wnt5a signaling is critical for macrophageinduced invasion of breast cancer cell lines. Proc Natl Acad Sci USA 103: 5454-5459, 2006.
32. Quasnichka H, Slater SC, Beeching CA, Boehm M, Sala-Newby GB, George SJ. Regulation of smooth muscle cell proliferation by β-catenin/ T-cell factor signaling involves modulation of cyclin D1 and p21 expression. Circ Res 99: 1329-1337, 2006.
33. Roarty K, Baxley SE, Crowley MR, Frost AR, Serra R. Loss of TGF-β or Wnt5a results in an increase in Wnt/β-catenin activity and redirects mammary tumour phenotype. Breast Cancer Res 11: R19, 2009.
34. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 361: 1533-1544, 2003.
35. Rzucidlo E, Martin K, Powell R. Regulation of vascular smooth muscle cell differentiation. J Vasc Surg 45: A25-A32, 2007.
36. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522-5527, 1999.
37. 2+ signaling by Wnt-5A. Dev Biol 182: 114-120, 1997.
38. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16: 3153-3162, 2010.
39. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 281: 9971-9976, 2006.
40. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999.
41. Vlad A, Röhrs S, Klein-Hitpass L, Müller O. The first five years of the Wnt targetome. Cell Signal 20: 795-802, 2008.
42. Xu YP, Zhu JJ, Cheng F, Jiang KW, Gu WZ, Shen Z, Wu YD, Liang L, Du LZ. Ghrelin ameliorates hypoxia-induced pulmonary hypertension via phospho-GSK3 beta/beta-catenin signaling in neonatal rats. J Mol Endocrinol 47: 33-43, 2011.
43. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, Chan AT, Sung JJ, Tao Q. Wnt5a exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 14: 55-61, 2008.